Press Releases
GEN Restaurant Group Secures Retail Placement at Save Mart Supermarkets with Six SKU Launch
CERRITOS, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- GEN Restaurant Group, Inc. (“GEN” or the “Company”) (Nasdaq: GENK), operator of GEN Korean BBQ, one of the largest full-service Korean BBQ restaurant chains in the United States, today announced that its consumer packaged goods products have been accepted for retail placement at Save Mart Supermarkets, a leading regional grocery chain across California and Nevada...
Eurofins Scientific: Director/PDMR Shareholding
LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM 1. Details of the person discharg...
Pony AI Inc. Announces Results of the Annual General Meeting
GUANGZHOU, China, June 8, 2026 /PRNewswire/ -- Pony AI Inc. ("Pony.ai" or the "Company") (NASDAQ: PONY; HKEX: 2026), a global leader in achieving large-scale mass production and commercialization of autonomous driving technology, today announced that each of the proposed resolutions submitted for shareholders' approval (the "Proposed Resolutions") as set forth in the notice of the annual general meeting dated April 22, 2026, Hong Kong time (the "AGM Notice"), has been adopted at the annual general meeting held in Guangzhou, China today. After the adoption of the Proposed Resolutions, all corporate authorizations and actions contemplated thereunder are approved, including, among other things, that (i) Mr...
Scorpio Gold Drills 1.27 g/t Gold over 45.23 Metres from 137.95 Metres Along Caldera Margin at Goldwedge
Highlights Hole 26MN-086 returned 1.27 g/t gold over 45.23 metres ("m") from 137.95 m, including 2.40 g/t gold over 7.47 m from 160.26 m and 8.06 g/t gold over 2.80 m from 172.31 m at Goldwedge. Vancouver, British Columbia--(Newsfile Corp. - June 8, 2026) - Scorpio Gold Corp. (TSXV: SGN) (OTCQB: SRCRF) (FSE: RY9) ("Scorpio Gold", or the "Company") is pleased to announce results from three step-out holes of the Phase Two drill program at the Manhattan District Project ("Manhattan"), Nevada, USA: 26MN-082, 26MN-084 and 26MN-086, see Figure 1...
Focus Graphite Completes Air Quality Assessment for the Lac Knife Project; Advancing Towards ESIA Completion
WSP Air Quality Assessment Confirms Regulatory Compliance and Further Advances Lac Knife Toward Permitting and Construction Readiness Ottawa, Ontario--(Newsfile Corp. - June 8, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the completion of the. Air Quality Assessment ("AQA" or the "Study") for its 100%-owned Lac Knife Graphite Project (the "Project") located in northeastern Quebec...
Yiren Digital Announces Increase in Beneficial Ownership by Mr. Ning Tang Following Controlling Shareholder Restructuring
BEIJING, June 8, 2026 /PRNewswire/ -- Yiren Digital Ltd. (NYSE: YRD) ("Yiren Digital" or the "Company"), a leading fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and global markets, today announced that it has been notified by CreditEase Holdings (Cayman) Limited, the Company's controlling shareholder (the "Controlling Shareholder"), that a change in the Controlling Shareholder's shareholding structure took place on June 5, 2026 (the "Restructuring")...
AMD Commits up to £2 Billion to Accelerate AI Innovation and Research in the United Kingdom
News Highlights: £2bn investment over five years to support advanced computing, scientific research and workforce development across the United Kingdom. New strategic partnerships with Imperial College London and Oriole Networks will help advance AI, quantum and next-generation computing research.
Innodisk Showcases Full Qualcomm Dragonwing Edge AI Lineup at Computex 2026, Spanning Dragonwing IQ8 Through IQ10
TAIPEI, June 8, 2026 /PRNewswire/ -- Innodisk, a leading global AI solution provider, showcases the full breadth of its collaboration with Qualcomm Technologies, Inc. at Computex 2026. Building on the "AI on Dragonwing" computing series launched earlier this year, Innodisk has rapidly expanded the edge platform lineup to span four generations of Qualcomm Dragonwing™ processors, delivering scalable performance from 20 to 700 TOPS across a broad spectrum of edge AI workloads...
WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards
DUNDALK, Ireland, June 8, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its Ireland site won the "Overall Excellence in Life Sciences" award, the highest recognition at the 2026 Life Sciences Industry Awards. The company also was named the winner of the "Life Sciences Team of the Year" and won the "Outstanding Contribution Award...
Willis expands its international property facility with up to USD 60 million ‘Follow' capacity per placement
LONDON, June 08, 2026 (GLOBE NEWSWIRE) -- Willis, a WTW business (NASDAQ: WTW), today announced the expansion of its international property facility, now able to offer up to USD 60 million of follow capacity per placement. The facility's expanded lead panel of Lloyd's syndicates is able to quote competitively across a range of primary and excess layers...
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab) lyophilized vial for intravenous administration...
BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - June 8, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, today announced that BioGene Therapeutics Inc. (the "Company"or 'BioGene"), a company that is a significant shareholder of, has appointed Ty Howton to BioGene's Board of Directors, effective immediately. Mr. Howton has extensive board and governance experience, having previously served as Board Counsel and Corporate Secretary for Solid Biosciences, AavantiBio, Sarepta Therapeutics, and Vertex Pharmaceuticals, as well as Advisor to the Board on Health Care Compliance at Genentech...
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU). “The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.” Abstracts accepted by EAACI include:
onsemi Introduces Industry-First Elite Pairing Studio to Simplify Power Design
Interactive simulation tool gives engineers visibility into device-level behavior and pairing trade-offs, accelerating power electronics design SCOTTSDALE, Ariz., June 08, 2026 (GLOBE NEWSWIRE) -- Summary The onsemi Elite Pairing Studio is an online design environment that simplifies pairing SiC MOSFETs and gate drivers for demanding power electronics applications, including AI data centers, electric vehicles, and industrial systems...
Share buybacks in Ericsson during the period June 1 - June 5, 2026
STOCKHOLM, June 8, 2026 /PRNewswire/ -- During the period June 1 - June 5, 2026, Telefonaktiebolaget LM Ericsson (publ) ("Ericsson") (LEI code 549300W9JLPW15XIFM52) repurchased own Class B shares (ISIN: SE0000108656) as follows: Date Aggregated daily volume (number of shares) Weighted average share price per day (SEK) Total daily transaction value (SEK) 01/06/2026 500,000 122.4013 61,200,650.00 02/06/2026 500,000 125.9387 62,969,350.00 03/06/2026 500,000 127.2936 63,646,800.00 04/06/2026 125,000 123.2703 15,408,787.50 05/06/2026 400,000 122.5939 49,037,560.00 Total 2,025,000 124.5744 252,263,147.50 The share repurchases are a part of the share buyback program of up to SEK 15,000,000,000 which Ericsson announced on April 16, 2026, and which runs between April 23, 2026, and March 31, 2027, at the latest. The Board of Directors intends to propose to the 2027 Annual General Meeting that the repurchased shares, other than those used to fulfil Ericsson's obligations under its share-related incentive programs, are cancelled...
Ingredion Announces Recommended All-Cash Acquisition of Tate & Lyle
Creates a scaled global provider of specialty ingredient solutions for a healthier, tastier and more sustainable future of food Broadens Ingredion's specialty ingredients platform across texturants, sugar reduction, and fortification, adding complementary capabilities in multi-ingredient systems and recipe development Expands Ingredion's ability to address customer needs across a wider range of end use categories and applications Brings together complementary geographic supply networks across the Americas, Europe, the Middle East and Africa, and Asia Pacific to deliver faster, more reliable and cost-effective ingredients and solutions for customers and consumers worldwide WESTCHESTER, Ill., June 08, 2026 (GLOBE NEWSWIRE) -- Ingredion Incorporated (NYSE: INGR) (“Ingredion”), a leading global provider of ingredient solutions to the food and beverage and industrial segments, today announced a recommended all-cash offer for the acquisition of Tate & Lyle PLC (“Tate & Lyle”), a global leader in mouthfeel, sweetening and fortification (the “Acquisition”)...
Trading in Storytel's BSshares on Nasdaq Stockholm's Main Market Commences
STOKHOLM, SE / ACCESS Newswire / June 8, 2026 / Storytel AB (publ) (STO:STORY B) - Storytel AB (publ) (the "Company") announced on 3 June 2026 that Nasdaq Stockholm's Listing Committee had approved the application for admission to trading of the Company's shares on Nasdaq Stockholm. Today, 8 June 2026, trading in the Company's B shares on Nasdaq Stockholm's Main Market commences...
Anoto Group AB (publ) announces an increase in conversion price from SEK 0.06 to SEK 0.12 for a new USD 0.6 million tranche under its convertible loan facility.
Anoto Group AB (publ) ("Anoto" or the "Company"), listed on Nasdaq Stockholm (ticker: ANOT), announces that it has entered into a second amended and restated convertible loan agreement, adding a new USD 0.6 million tranche to its existing convertible financing framework.
Nebius expands in UK with more NVIDIA-powered infrastructure, more customers, and more cloud capabilities for agentic and enterprise AI
LONDON--(BUSINESS WIRE)--Nebius (Nasdaq: NBIS), the AI cloud company, today announced it is investing approximately £1.7 billion to build out capacity in the UK with three new deployments of NVIDIA infrastructure, as the company continues to expand its commercial and AI R&D hub in London. Nebius launched its first UK deployment of NVIDIA Blackwell Ultra infrastructure in November 2025. The three new sites will also deploy the latest generations of NVIDIA's full-stack, end-to-end AI factory...
InterContinental Hotels Group PLC Announces Transaction in Own Shares - June 08
Purchase of own shares LONDON, UK / ACCESS Newswire / June 8, 2026 / InterContinental Hotels Group PLC (the "Company"), The Company announces that on 05 June 2026 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 8 May 2025 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 17 February 2026, as announced on 17 February 2026...
Touchstone Exploration Inc. Final Results of Fundraise and of Wrap Retail Offer
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT...
Rackspace Technology Establishes Regional Headquarters in Riyadh to Accelerate Cloud and AI Growth
RIYADH, Saudi Arabia, June 08, 2026 (GLOBE NEWSWIRE) -- Rackspace Technology (NASDAQ: RXT), a global enterprise AI infrastructure and solutions provider, today announced the establishment of its regional headquarters in Riyadh, Saudi Arabia, reinforcing the company's long-term commitment to the Kingdom of Saudi Arabia and the broader Middle East region. The new regional headquarters will serve as a strategic hub for Rackspace Technology's operations and customer engagement efforts, supporting organizations across enterprise, government, and regulated industries as they accelerate digital transformation initiatives aligned with Saudi Arabia's Vision 2030 agenda...
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Strategic collaboration combines Nurix's leadership in targeted protein degradation with Roche's portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clinical development plan in malignant hematology builds on the ongoing pivotal program in chronic lymphocytic leukemia (CLL) and includes therapeutic combination regimens across B cell malignancies Clinical development plan also includes expansion into neurology and immunology with plans for Phase 2 trials in multiple sclerosis (MS) and chronic spontaneous urticaria (CSU) Nurix to receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milestones for potential total payments of up to $2.3 billion; profits and losses to be shared equally in the United States with Nurix receiving royalties on ex-U.S. sales Nurix to host a conference call tomorrow, June 8 at 8 a.m. ET BRISBANE, Calif...
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignancies Collaboration adds to Roche's oncology pipeline and offers potential indications in immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis) Bexobrutideg utilises a novel approach to eliminate the Bruton's Tyrosine Kinase (BTK) protein, potentially overcoming existing resistance mechanisms found with current standard-of-care BTK inhibitors Basel, 08 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics, Inc. (Nasdaq: NRIX). Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialise bexobrutideg (NX-5948), Nurix's investigational Bruton's Tyrosine Kinase (BTK) degrader...
WISeKey, The Hashgraph Group and Hedera Launch QAIT Q-Day Security Assessment Platform on the SEALCOIN Quantum Marketplace
WISeKey, The Hashgraph Group and Hedera Launch QAIT Q-Day Security Assessment Platform on the SEALCOIN Quantum Marketplace First Quantum Security Service to Launch Within SEALCOIN's Dedicated Quantum Marketplace, Enabling Organizations to Assess and Prepare for Quantum-Era Cybersecurity Risks Geneva, Switzerland – June 8, 2026 — WISeKey International Holding Ltd (SIX: WIHN; NASDAQ: WKEY), a global leader in cybersecurity, digital identity and IoT, today announced the launch of a dedicated Quantum Marketplace within the SEALCOIN platform and the introduction of its flagship application, the QAIT Q-Day Security Assessment Platform. Developed in collaboration with The Hashgraph Group (THG) and Hedera, the platform is designed to help enterprises, governments and critical infrastructure operators evaluate, monitor and mitigate cybersecurity risks associated with the emergence of quantum computing...
Digital Realty Launches Malaysia Operations to Advance Southeast Asia's Digital Connectivity
Cyberjaya campus integrates Malaysia into Digital Realty's global network, enabling customers to deploy AI and data-driven workloads across a connected infrastructure Cyberjaya campus integrates Malaysia into Digital Realty's global network, enabling customers to deploy AI and data-driven workloads across a connected infrastructure
New IBM Study Finds CIOs and CTOs Face Growing AI Control Gap as Enterprise Deployment Scales
Most surveyed technology leaders are accountable for systems they don't fully control Only 11% of respondents say they're completely prepared for the scale of AI agent deployment Organizations that design control into their AI systems achieve significantly stronger performance outcomes. ARMONK, N.Y.
Rumble Announces Final Results of Exchange Offer for Northern Data
Rumble Has Successfully Secured the Support of 85% of Northern Data's Share Capital In Total, 46% of Northern Data Shares not subject to Transaction Support Agreements Have Been Tendered Additional Acceptance Period Expired on June 1, 2026 – Exchange Offer No Longer Open for Acceptance Closing Expected in mid-June 2026, with application for Delisting of Northern Data Shares expected to be filed immediately Afterwards Transaction Follows Compelling Strategic Rationale Longboat Key, FL, June 08, 2026 (GLOBE NEWSWIRE) -- Rumble Inc. (NASDAQ: RUM) (“Rumble”), the Freedom-First technology platform, today announced the final results for its exchange offer to acquire all outstanding shares of Northern Data AG (“Northern Data”). A total of 8,174,379 shares were tendered in the offer, representing 46.2% of shares not subject to transaction support agreements...
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region
DUBAI, United Arab Emirates & NEW YORK--(BUSINESS WIRE)--BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA's established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating unde...
Oasis Calls on KADOKAWA Investors to Vote AGAINST CEO Takeshi Natsuno at 2026 AGM (Securities Code: 9468 JT): Frequently Asked Questions
HONG KONG--(BUSINESS WIRE)--Oasis Management Company Ltd. (TOKYO: 9468): Q1. Who is Oasis, and how long has Oasis been engaged with KADOKAWA? Oasis Management Company Ltd. (“Oasis”) is a long-term, research-driven investment manager whose funds have been shareholders of KADOKAWA CORPORATION (“KADOKAWA” or the “Company”) since 2020 and currently own approximately 13.76% of the Company's shares. Over the past six years, Oasis has engaged extensively with KADOKAWA's management and Board through me...
Solidion Technology Announces $35 Million Private Placement of Common Stock Priced Above Market Under Nasdaq Rules
Proceeds fully fund the company through 2028 and will be used to accelerate commercialization of Solidion's patented Extreme-Climate Battery Technology targeting the Lunar economy and space applications
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes Association (ADA) 2026 Scientific Sessions (taking place June 5-8, 2026, in New Orleans, Louisiana), highlighting its differentiated portfolio in obesity treatment, including small-molecule candidates, a peptide therapeutic, and an oral peptide delivery-enhancing technology. The data attracted considerable interest from leading experts at the meeting and further underscored Ascletis' innovation capabilities in metabolic disease therapeutics...
GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company
Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas
Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Announces Upcoming EAI Robotics Major Launch Events in June, Along with the First Cooperation Agreement with U.S. K-12 Public School
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today shared a weekly business update from YT Jia, Founder and Global CEO of FF. “Hello from issue 58 of our weekly report. This week, I would like to share two key updates with everyone: first, our upcoming major launch events; and second, an important breakthrough in our robotics education ecosystem. Sin...
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027
Odysight.ai® Establishes At-The-Market (ATM) Program of up to $20 Million to Enhance Financial Flexibility
Ramat Gan, Israel, June 07, 2026 (GLOBE NEWSWIRE) -- Odysight.ai (NASDAQ/TASE: ODYS) today announced that, as part of a planned step to expand the Company's financing toolkit in the U.S. capital market, it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (SEC) under which it may offer and sell from time to time and at its discretion shares of its common stock having an aggregate offering price of up to $20 million pursuant to an At-The-Market (ATM) program with the investment bank Roth Capital Partners. The program provides the Company with an additional, flexible financing infrastructure that can be utilized at the Company's discretion to support business development and capitalize on market opportunities...
SK Telecom and NVIDIA Build AI Infrastructure to Power Korea's AI Innovation
Korea's Leading Telco to Add NVIDIA-Powered AI Cloud Capacity Built on NVIDIA DSX AI Factory Architecture to Accelerate AI Startups, Robotics and Industrial Physical AI Korea's Leading Telco to Add NVIDIA-Powered AI Cloud Capacity Built on NVIDIA DSX AI Factory Architecture to Accelerate AI Startups, Robotics and Industrial Physical AI
NVIDIA and SK hynix Announce Multiyear Technology Partnership to Advance Memory for AI Factories
Collaboration Supports Next-Generation Memory Codevelopment With NVIDIA's AI Infrastructure Roadmap and Expands Supply for the Accelerating Global AI Factory Buildout Collaboration Supports Next-Generation Memory Codevelopment With NVIDIA's AI Infrastructure Roadmap and Expands Supply for the Accelerating Global AI Factory Buildout
NAVER Expands AI Infrastructure With NVIDIA to Serve Surging Global AI Demand
NAVER to Build NVIDIA DSX-Based AI Factories at Gigawatt Scale to Power Agents and Physical AI NAVER to Build NVIDIA DSX-Based AI Factories at Gigawatt Scale to Power Agents and Physical AI
Entrata Collaborates with OpenAI to Define the Future of Autonomous Property Management
New agreement with OpenAI brings additional AI agents to rental housing at scale, transforming how properties operate and how residents experience their homes New agreement with OpenAI brings additional AI agents to rental housing at scale, transforming how properties operate and how residents experience their homes
VolitionRx Announces Pricing of $4.6 Million Public Offering
$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrants HENDERSON, Nev., June 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the pricing of its previously announced public offering of 2,960,000 shares of common stock, and warrants to purchase up to an aggregate of 1,480,000 shares of common stock, at a combined public offering price of $1.55 per share and accompanying half warrant...
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
VESALIUS-CV Subgroup Results Show Repatha Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes New Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes Care THOUSAND OAKS, Calif., June 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to addressing unmet needs for people living with cardiometabolic conditions and improving patient outcomes...
GoHealth, Inc. to strengthen its position ahead of AEP 2026 through Restructuring Process supported by key stakeholders
Initiates voluntary prepackaged Chapter 11 process to implement Restructuring Transactions that have the support of 100% of its lenders, over 60% of the holders of GoHealth, Inc. Class A Common Stock, and over 99% of the holders of GoHealth Holdings, LLC interests.
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis
Company announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP-1 dual agonist, from baseline.1 Detailed pre-specified analysis from a sub study of SYNCHRONIZE-1 show that, relative to baseline, survodutide achieved a reduction of up to 34% in visceral fat, with the proportion of lean mass loss reflecting no more than 10.8% of change in total tissue mass at the highest dose, alongside an up to 63.1% reduction of liver fat, indicating a targeted reduction in metabolically harmful fat after 76 weeks.2,3 Detailed results presented from SYNCHRONIZE-MASLD, showed that the trial met both its primary endpoints, with additional results showing that, relative to baseline, liver fat normalization was reached by 6 out of 10 participants living with metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity or overweight who were treated with survodutide after 48 weeks.4 The SYNCHRONIZE-1 and SYNCHRONIZE-MASLD results were presented at the American Diabetes Association's (ADA) 2026 Scientific Sessions and simultaneously published in The New England Journal of Medicine and Nature Medicine, respectively.5,6 Copenhagen, Denmark, June 7, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no...
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%) In ATTAIN-2, women taking Foundayo lost significant weight across all stages of menopause, despite the additional challenge of living with type 2 diabetes Across studies, women taking Foundayo saw meaningful reductions in their waist circumference, a measure associated with reduced abdominal fat and cardiometabolic risk INDIANAPOLIS, June 7, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results demonstrating that women with obesity or overweight who took the highest dose of Foundayo experienced significant weight loss at every stage of menopause. These findings, based on post-hoc analyses of more than 1,500 female participants in the ATTAIN-1 and ATTAIN-2 clinical trials, were presented at the American Diabetes Association (ADA) 86th Scientific Sessions...
Unlocking the Americas: Air Canada and Abra Group Sign Memorandum to Expand Travel and Connectivity between Canada, Latin America and Beyond
RIO DE JANEIRO, June 07, 2026 (GLOBE NEWSWIRE) -- Air Canada and Abra Group today announced they have signed a Memorandum of Understanding to develop a broad, long-term strategic partnership. The agreement between Canada's largest airline and the Latin American air transport company, whose carriers include the Avianca and GOL brands, would enable the partners to expand their global reach, providing customers and shippers greater connectivity across North, Central and South America and beyond. Any final agreement is subject to final documentation and regulatory approval...
Microcap, Penny Stock, and Institutional Investors Across the Globe Are Discovering a Unique Opportunity in Elektros Inc.
An Opportunity to Own Equity in Lithium Mining, Rare Earth Minerals, and EV Patent Technology Through Elektros Inc. WEST PALM BEACH, FL / ACCESS Newswire / June 6, 2026 / Elektros Inc. (Ticker:ELEK) continues to advance its vision of participating in key sectors that many investors view as important to the future of global electrification and energy infrastructure. The Company's strategic focus includes lithium mining opportunities, rare earth mineral initiatives, and proprietary electric vehicle patent technology designed to address evolving transportation and energy demands...
Duke Energy offers tips to save energy and money as temperatures rise in the Carolinas
What's happening: Temperatures are forecast to reach the 90s, pushing cooling systems to run longer and use more energy to maintain indoor temperatures Why it matters: Acting now with a few simple steps can help reduce energy use during the heat wave CHARLOTTE, N.C., June 6, 2026 /PRNewswire/ -- High temperatures are forecast across the Carolinas this weekend and next week, and Duke Energy has tips to help you take control of your energy use while keeping you and your family cool...
Bouygues Telecom takes a major step forward for its future growth by signing, alongside Free-iliad Group and Orange, a Memorandum of Understanding with Altice France with a view to acquiring SFR
Press release Paris, 6 June 2026 Bouygues Telecom takes a major step forward for its future growth by signing, alongside Free-iliad Group and Orange, a Memorandum of Understanding with Altice France with a view to acquiring SFR. Bouygues Telecom today has signed a Memorandum of Understanding, alongside Orange and Free-iliad Group (the “Consortium”), with Altice France with a view to acquiring SFR...
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of...
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting the BMI criteria for obesity In addition to weight loss, retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.1%) and moderate-to-severe obstructive sleep apnea severity by up to 36.1 events per hour (60.6%) In TRANSCEND-T2D-1, participants on retatrutide achieved A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs (16.8%) at 40 weeks, with up to 46% achieving a normal A1C INDIANAPOLIS, June 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced additional positive results from pivotal Phase 3 trials of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, showing substantial weight loss along with meaningful improvements across knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and type 2 diabetes – common obesity-related conditions.1,2 The findings from TRIUMPH-1 and TRANSCEND-T2D-1 were presented at the American Diabetes Association (ADA) 86th Scientific Sessions, with TRANSCEND-T2D-1 results simultaneously published in The Lancet. "Obesity drives more than 200 downstream diseases, yet we have historically treated those conditions one at a time and in silos," said Ania Jastreboff, M.D...
All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration
NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) -- All In FutureTech Alliance (Nasdaq: AIFA) (“AIFA” or the “Company”) today provided a strategic update. Following the Company's previously announced signing of agreements to acquire a controlling interest in HyalRoute Communication Group (“HyalRoute”) and advancement of the Hainan AIFA Silicon Photonics Supercomputing Center project, the Company is further accelerating project planning, policy coordination, financing arrangements, and cross-border resource integration around its dual-engine strategy of an “AI infrastructure network powered by optical technologies” and an “AI application services matrix.”
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented detailed results from multiple Phase 2b studies of berobenatide (PF'3944), an investigational, potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, during a late-breaking expert symposium at the 86th Scientific Sessions of the American Diabetes Association (ADA). The objectives for the Phase 2 studies were to identify the right doses for Phase 3 and to test escalation schemes. Across both weekly and monthl...
New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect early Ketone monitoring is not yet routine in diabetes care, which may contribute to missed warning signs of DKA and delays in intervention Nearly 60% of pediatric hospitalizations for Type 1 diabetes in the U.S. are associated with DKA1 ABBOTT PARK, Ill., June 6, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected health concern for people living with both Type 1 and Type 2 diabetes...
Battery X Metals Announces Closing of First Tranche of Private Placement to Advance Corporate Growth
VANCOUVER, BC / ACCESS Newswire / June 5, 2026 / Battery X Metals Inc. (CSE:BATX)(OTCQB:BATXF)(FSE:5YW0, WKN:A41RJF) ("Battery X Metals" or the "Company") an energy transition resource exploration and technology company, announces that, further to its news release dated May 22, 2026, the Company has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Private Placement"), through the issuance of 218,182 units of the Company (each, a "Unit") at a price of $2.75 per Unit, for aggregate gross proceeds of $600,000.50. Each Unit consists of one common share in the capital of the Company (each, a "Share") and one transferable common share purchase warrant (each, a "Warrant")...
Promino Announces Settlements and Amendments of Convertible Debentures
Burlington, Ontario--(Newsfile Corp. - June 5, 2026) - Promino Nutritional Sciences, Inc. (CSE: MUSL) (OTCID: MUSLF) (FSE: 93X) ("Promino" or the "Company") announces that it has agreed to settle $373,910 in principal and accrued interest of convertible debentures through the issuance of 5,341,566 common shares at a deemed issue price of $0.07. In addition, certain convertible debentures, originally issued on June 30 and July 14, 2023, having an aggregate principal amount of $711,500, have been amended as follows: 1) maturity dates have been extended for a further two year period to June 30 and July 14, 2027; and 2) conversion prices have been amended from $0.30 per unit to $0.07 per common share...
Lockheed Martin Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lockheed Martin Corporation - LMT
NEW YORK and NEW ORLEANS, June 5, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
Roblox Investigation Initiated: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Roblox Corporation - RBLX
NEW YORK and NEW ORLEANS, June 5, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering
New York, NY, June 05, 2026 (GLOBE NEWSWIRE) -- InterPrivate Investment Partners V, Inc. (the “Company”), a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, announced the closing of its initial public offering of 20,125,000 units, including 2,625,000 units issued pursuant to the exercise of the underwriters' over-allotment option in full, at a price of $10.00 per unit on June 5, 2026. Total gross proceeds from the offering were $201.25 million before deducting underwriting discounts and commissions and other offering expenses payable by the Company...
McFarlane Lake Mining Provides Update on Investor Relations and Marketing Service Engagements
TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- McFarlane Lake Mining Limited (“McFarlane” or the “Company”) (CSE: MLM, OTC: MLMLF) announces the continuation and renewal of its investor relations and marketing service engagements with Alliance Advisors Investor Relations (“Alliance Advisors IR”), The Market Link (“Market Link”) and Emerging Markets Consulting (“EMC”)...
Command the Clone Wars'™ Most Cunning Operatives in Star Wars Zero Company™, Launching August 27
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Electronic Arts Inc. (NASDAQ: EA) today announced that Star Wars Zero Company™, a single-player turn-based tactics game, developed by Bit Reactor in collaboration with Lucasfilm Games, will be available on PC, PlayStation 5 and Xbox Series X|S starting August 27, 2026. Pre-Orders are now available on all platforms. A new gameplay trailer delivers an action-packed look at the game's gritty, cinematic take on turn-based tactics while previewing an original...
Argo Corporation Announces Closing of Strategic Investment
TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- Argo Corporation (TSXV: ARGH), (OTCQX: ARGHF) (“Argo” or the “Company”), a leader in next-generation transit solutions, announces that it has closed a non-brokered private placement with a strategic investor whose business is related to the manufacturing of potential future vehicle hardware...
Digicann Ventures Announces Proposed Reverse Takeover Transaction with Winning Asia Technology Macau Limited
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - Digicann Ventures Inc. (CSE: DCNN.X) ("Digicann" or the "Company"), is a reporting issuer listed on the Canadian Securities Exchange (the "CSE"). The Company is currently focused on identifying and completing a qualifying business combination transaction, is pleased to announce that it has entered into a non-binding letter of intent dated May 29, 2026 (the "LOI") with Winning Asia Technology Macau Limited ("WAT"), a private technology company governed under the laws of Macau SAR, pursuant to which the parties intend to complete a business combination transaction (the "Transaction")...
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants
Purecore Announces up to $1.5 Million Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS.
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with v omiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectively Phase 1 single ascending dose trial, the first ribupatide injection clinical data generated outside of China, demonstrated similar exposure, tolerability, and weight reduction in participants of Asian and non-Asian descent SHANGHAI and WALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced clinical results for ribupatide (also known as HRS9531 or KAI-9531), a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight, presented at the 86th Scientific Sessions of the American Diabetes Association (ADA)...
South Pacific Metals Engages Marketing Services and Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - South Pacific Metals Corp. (TSXV: SPMC) (OTCQB: SPMEF) (FSE: 6J00) ("SPMC" or "South Pacific Metals" or the "Company") announces that it has entered into an online marketing agreement dated June 5, 2026, with i2i Marketing Group, LLC ("i2i"), pursuant to which i2i will provide corporate marketing and investor awareness services to the Company, including, but not limited to, content creation management, author sourcing, project management and media distribution (the "Agreement"). The Company has agreed to an initial creation and media budget of US$300,000 (the "Initial Media Budget")...
Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK, June 5, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 22, 2026, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range...
SmartStop Self Storage Named One of Reviewed's Best National Storage Chains of 2026
LADERA RANCH, Calif.--(BUSINESS WIRE)--SmartStop Self Storage REIT, Inc. (“SmartStop”) (NYSE: SMA), an internally managed real estate investment trust and a premier owner and operator of self-storage facilities in the United States and Canada, announced its inclusion in Reviewed's Best National Storage Chains of 2026. Notably, SmartStop earned the distinction of being the highest-ranked publicly traded self-storage company on this year's list. The annual rankings, determined by reader voting, s...
A.I.S. Resources Announces Grant of Options
VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- A.I.S. Resources Limited (TSXV: AIS, OTC-Pink: AISSF, FRA: 5YH) (“A.I.S.” or the “Company”) announces the Company has granted a total of 1,000,000 incentive stock options to a director of the Company in accordance with the Company's stock option plan. Each Option is exercisable into one common share of the Company at a price of $0.15 per share. The Options were granted on June 5, 2026, vested on the date of grant and have a term of five years from the date of grant. The stock options granted are subject to the acceptance of the TSX Venture Exchange...
B2Gold Announces Voting Results from its 2026 Annual General and Special Meeting
VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) -- B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on Thursday, June 4, 2026. A total of 842,480,659 common shares were voted at the Meeting, representing 63.06% of the votes attached to all outstanding common shares...
Western Union Reports Inducement Grants Under New York Stock Exchange Listing Rule 303A.08
DENVER--(BUSINESS WIRE)--The Western Union Company (NYSE: WU) today announced that it issued inducement awards to two new non-executive employees under the New York Stock Exchange's Listing Rule 303A.08. The awards were granted as restricted stock units (RSUs) with respect to an aggregate of 267,380 shares of the Company's common stock and were granted as of June 5, 2026. These awards were granted in connection with the employment of certain key employees who will be supporting the execution of...
Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for Information
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) to determine whether certain Beta Bionics officers and directors violated securities laws and breached fiduciary duties to shareholders. Beta Bionics is a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes...
Pics N.V. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in PICS Due to Possible Violations of Securities Laws
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP reminds investors it is investigating Pics N.V. (NASDAQ: PICS) to determine whether certain Pics N.V.
Robbins LLP Reminds SLP Stockholders of its Investigation into Simulation Plus, Inc.; Contact the Firm for Information
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain Simulation Plus officers and directors violated securities laws and breached fiduciary duties to shareholders. Simulation Plus is a software company serving the pharmaceutical, biotechnology, and chemical industries...
Onco-Innovations Signs LOI with Nanosoft Polymers to Advance Polymer and Drug Delivery Development for the ONC010 Program
VANCOUVER, BC / ACCESS Newswire / June 5, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered into a non-binding Letter of Intent ("LOI") with Nanosoft Polymers ("Nanosoft"), a biotechnology-focused polymer company, as an initial step toward negotiating a services agreement related to polymer process development, analytical characterization, and drug formulation optimization activities for the Company's exclusively licensed PNKP Inhibitor Technology, ONC010. The LOI is non-binding, and there is no certainty that a services agreement will be entered into...
Knight Announces Early Warning Filing Regarding Shares of Crescita
MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) -- This press release is disseminated by Knight Therapeutics Inc. ("Knight") (TSX:GUD), a pan-American (ex-US) pharmaceutical company, as required by Regulation 62-103 respecting the Early Warning System and Related Take-Over Bid and Insider Reporting Issues regarding securities of Crescita Therapeutics Inc. ("Crescita")...